Key facts
- This page summarizes Jonathan E. Lim's Form 3 filing for Boundless Bio, Inc. (BOLD).
- 0 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 27 Mar 2024, 20:00.
Jonathan E. Lim - 27 Mar 2024 Form 3 Insider Report for Boundless Bio, Inc. (BOLD)
- Reporting relationship
- Director
- Issuer ticker
- BOLD
- Reported as of
- 27 Mar 2024
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 27 Mar 2024, 20:00:22 UTC
- Prior SEC filing
- 07 Feb 2024
- Next SEC filing
- 04 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jessica Oien, Attorney-in-Fact for Jonathan Lim
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan E. Lim filed Form 3 for Boundless Bio, Inc. (BOLD) on 27 Mar 2024.
Change
- Previous filing in this sequence was filed on 07 Feb 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BOLD
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 102,564
- Date
- 27 Mar 2024
- Ownership
- Direct
BOLD
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 25,641
- Date
- 27 Mar 2024
- Ownership
- By City Hill, LLC
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BOLD
holding
Derivative
Series A Convertible Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 27 Mar 2024
- Ownership
- By City Hill, LLC
- Underlying class
- Common Stock
- Underlying amount
- 512,820
- Exercise price
- Footnotes
- F1, F2
BOLD
holding
Derivative
Series B Convertible Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 27 Mar 2024
- Ownership
- By City Hill, LLC
- Underlying class
- Common Stock
- Underlying amount
- 5,128
- Exercise price
- Footnotes
- F1, F2
BOLD
holding
Derivative
Series C Convertible Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 27 Mar 2024
- Ownership
- By City Hill, LLC
- Underlying class
- Common Stock
- Underlying amount
- 7,326
- Exercise price
- Footnotes
- F1, F2
BOLD
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 27 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,256
- Exercise price
- $4.10
- Footnotes
- F3
BOLD
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 27 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,435
- Exercise price
- $4.10
- Footnotes
- F4
BOLD
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 27 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,846
- Exercise price
- $8.19
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein.
Footnote F2
Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.
Footnote F3
The stock option vests in 36 substantially equal monthly installments beginning on July 7, 2021.
Footnote F4
The stock option vests in 36 substantially equal monthly installments beginning on July 13, 2023.
Footnote F5
The stock option vests in 36 substantially equal monthly installments beginning on March 15, 2024.
SEC remarks
Exhibit 24 - Power of Attorney.